Overview

Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)

Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of single injection of it-hMSC in patients with ischemic stroke in a multicenter, blind, randomized, placebo controlled trial
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Collaborator:
Beijing Tiantan Hospital